GENova Gains Access To Bridge BioResearch’s Distribution Channels

GENova Biotherapeutics (GENova) has gained access to distribution channels for its drug targets through a recently-signed deal with Bridge BioResearch.

Through a recent collaboration deal, the two companies are working together to leverage their respective Research and Development partners and distribution channels worldwide, with the mutual goal of developing their proprietary drug targets with the utmost cost and time efficiency.

Aaron Whiteman, CEO for GENova, said: “This reciprocal arrangement is a huge benefit to both companies. I am confident that with our new access to Big Pharma distribution channels we can usher our patents through the development process as expeditiously as possible, and ultimately start reaping royalty payments sooner than ever foreseen.”